ReviewMemo2017
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update.
Review in Memo, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Angiosarcoma-related cerebral metastases: a systematic review of the literature.Neurosurgical review · 2020Pooled it
- Patient-partnered multiomics reveals the molecular architecture of angiosarcoma.Nature communications · 2026Article
- Primary renal angiosarcoma with renal vein thrombus: Case report and Review of literature.Urology case reports · 2026Article
- Cardiac Angiosarcoma in a 17-Year-Old Female: A Rare Case Report and Literature Review.Cureus · 2025Article
- Article
- Case Report: A novel chemotherapy-free regimen combined with photodynamic therapy, target therapy, and immunotherapy in a geriatric male with huge recurrent scalp and facial angiosarcoma: a report of an extremely rare case and literature review.Frontiers in immunology · 2025Review
- Clinical characteristics of primary pulmonary hemangiosarcoma outcomes: a Surveillance, Epidemiology, and End Results database analysis.American journal of translational research · 2025Article
- Cardiac angiosarcoma with lung metastasis presented with multiple halo signs: One case report and literature review.Radiology case reports · 2024Article
- Pediatric primary intracranial angiosarcoma with epithelioid differentiation: a surgeon's dilemma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Molecular Profile of Canine Hemangiosarcoma and Potential Novel Therapeutic Targets.Veterinary sciences · 2023Review
- Primary cerebral epithelioid angiosarcoma: a case report.BMC neurology · 2023Article
- Primary Cutaneous Angiosarcoma of the Scalp with Cranial Invasion in a Patient with Metastatic Breast Cancer.The Journal of clinical and aesthetic dermatology · 2021Article
- Endoglin in the Spotlight to Treat Cancer.International journal of molecular sciences · 2021Review
- Neoadjuvant Systemic Treatment of Primary Angiosarcoma.Cancers · 2020Review
- Clinical outcomes in primary scalp angiosarcoma.Oncology letters · 2019Article
- Angiosarcoma of the breast, the unknown-a review of the current literature.Translational cancer research · 2019Review
- Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro.Scientific reports · 2019Article
- Malignant hepatic vascular tumors in adults: Characteristics, diagnostic difficulties and current management.World journal of clinical oncology · 2019Review
- Angiosarcoma: a review of diagnosis and current treatment.American journal of cancer research · 2019Review
- Pulmonary epithelioid angiosarcoma responsive to chemotherapy: A case report.Radiology case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents. A number of small prospective studies have reported angiosarcoma response to vascular-targeted agents, including agents that target vascular endothelial growth factor. To date, the response to these agents has been disappointing, and similar to the response observed in other soft tissue sarcoma subtypes. This short review will summarise the recent data in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.